Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab
Top Cited Papers
Open Access
- 26 November 2019
- Vol. 8 (12), 1522
- https://doi.org/10.3390/cells8121522
Abstract
CD38 is a transmembrane glycoprotein with ectoenzymatic activity involved in regulation of migration, signal transduction, and receptor-mediated adhesion. CD38 is highly expressed on various malignant cells, including multiple myeloma (MM), and at relatively low levels in other tissues, making it a suitable target for therapeutic antibodies. Several anti-CD38 therapies have been, or are being, developed for the treatment of MM, including daratumumab and isatuximab (SAR650984), respectively. Studies have shown that anti-CD38 therapies are effective in the treatment of relapsed/refractory MM and are well tolerated, with infusion reactions being the most common side effects. They can be used as monotherapy or in combination with immunomodulatory agents, such as pomalidomide, or proteasome inhibitors to potentiate their activity. Here we examine isatuximab and several anti-CD38 agents in development that were generated using new antibody engineering techniques and that may lead to more effective CD38 targeting. We also summarize trials assessing these antibodies in MM, other malignancies, and solid organ transplantation. Finally, we propose that further research on the mechanisms of resistance to anti-CD38 therapy and the development of biomarkers and new backbone regimens with CD38 antibodies will be important steps in building more personalized treatment for patients with MM.Keywords
This publication has 99 references indexed in Scilit:
- The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategiesBlood Cancer Journal, 2012
- Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myelomaLeukemia, 2012
- The state of therapy for removal of alloantibody producing plasma cells in transplantationSeminars in Immunology, 2012
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapiesBlood Cancer Journal, 2011
- Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategiesBlood, 2011
- Multiple MyelomaThe New England Journal of Medicine, 2011
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumabHaematologica, 2010
- Bortezomib: a new player in pre- and post-transplant desensitization?Nephrology Dialysis Transplantation, 2010
- Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney TransplantationJournal of the American Society of Nephrology, 2010
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008